Selumetinib Shows Promise in Metastatic Uveal Melanoma.

Published July 14, 2013

Selumetinib Shows Promise in Metastatic Uveal Melanoma.

Cancer Discov. 2013 Jul; 3(7): OF8

Compared with temozolomide chemotherapy, the MEK inhibitor selumetinib extended progression-free survival by nearly 9 weeks in patients with melanoma of the eye participating in a phase II trial, making it the first effective drug for the rare disease. HubMed – drug

PD-1 Inhibitor Becomes “Breakthrough Therapy”

Cancer Discov. 2013 Jul; 3(7): OF14

Merck’s lambrolizumab (MK-3475) monoclonal antibody received “Breakthrough Therapy” designation from the U.S. Food and Drug Administration in April for treating patients with advanced melanoma. The designation is one of many signs of progress in attacking cancer with agents designed for immune checkpoint blockade. HubMed – drug

MCCA Connecticut Drug and Alcohol Rehabilitation Danbury CT
MCCA Connecticut Drug and Alcohol Rehabilitation Danbury CT http://local.ctpost.com/b26201026/MCCA+Connecticut+Drug+and+Alcohol+Rehabilitation?type= substanc…